New York, Nov. 17, 2023 PRISM MediaWire - Weekly Press Resume Nov. 13 to Nov. 17, 2023 Ethical Web AI Launches AI Seek 4.0 with Almost Real-Time Data https://prismmediawire.com/ethical-web-ai-launches-ai-seek-4-0-with-almost-real-time-data/ AmpliTech to Host Quarterly Investor Call to Review Q3 2023 Earnings on Tuesday November 14, 4:30 PM ET; Dial-in # 1-833-630-0019 or 1-412-317-1807...
NEW YORK, NY, November 14, 2023 - PRISM MarketView, a leader within the financial markets and news community, has debuted its PRISM Emerging Public Health Index. https://prismmarketview.com/index/public-health/ The Public Health segment highlights the most critical health crises impacting the world’s population today - including dementia, diabetes, stroke, hypertension and heart disease - as identified by the World Health Organization (WHO). The PRISM Public Health index focuses on the...
Company to Host a Conference Call and Webcast on November 14, 2023, at 10:30 am EDT POMPANO BEACH, FLORIDA, November 13, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended September 30, 2023. Jason Matuszewski, Chief Executive Officer of BioStem Technologies Inc. said, “2023 has been a remarkable year of growth...
New York, New York, Nov. 10, 2023 PRISM MediaWire - Weekly Press Resume Nov. 6 to Nov. 10, 2023 Two Hands Corporation Launches Sports Illustrated Line Protein Bars in Canada https://prismmediawire.com/two-hands-corporation-launches-sports-illustrated-line-protein-bars-in-canada/ BioStem Technologies to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023...
-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, CA, November 09, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial revenue is...
POMPANO BEACH, FLORIDA, November 8, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture and commercialization of placental-derived biologics for advanced wound care, today announced that the Centers for Medicare and Medicaid Services (CMS) has published a new Q code, Q4279 for VENDAJE AC® pursuant to its application for Healthcare Common Procedure Coding System (HCPCS) “Q” codes. The HCPCS code assigned for VENDAJE...
POMPANO BEACH, FLORIDA, November 6, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today that it plans to release its third quarter 2023 financial results pre-market on Tuesday, November 14, 2023. BioStem will host a conference call and webcast at 10:30am ET on Tuesday, November 14, 2023. The call will include a discussion of...
POMPANO BEACH, FLORIDA, November 3, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announces that it has closed an oversubscribed private placement of common stock to accredited investors for an aggregate of 1,337,000 units (each, a “Unit”) at a price of $1.50 per Unit for gross proceeds of $2 million. Each Unit consists of one...
Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, November 3, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issued the same day,...
NEW YORK, NY, October 24, 2023 - The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in the sector. Consequently, many small and micro-cap biotech companies are trading at all-time lows, with several down by over 80-90% in recent years. This downturn has led to many biotech firms trading below their cash...
Study to support differentiated efficacy of Vendaje® structural tissue allograft POMPANO BEACH, FLORIDA, October 24, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announced that the first site is now fully opened for its clinical trial, evaluating the Vendaje® tissue allograft in the treatment of diabetic foot ulcers (DFU). Jason...
Index Highlights Innovative Companies Addressing the Unseen Challenges of Mental Disorders New York City, October 11, 2023 - In honor of World Mental Health Day, which raises awareness of mental health issues on a global scale, PRISM MarketView has introduced the Prism Emerging Mental Health Index, a proprietary index focused on pioneering stocks offering innovative treatments for mood issues, anxiety, personality disorders and more....
Interventional study compares VitaGraft to current transplant rejection monitoring protocols Oncocyte’s VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p<0.001) IRVINE, CA, September 18, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the European Society of Organ Transplant (ESOT) conference. The data was generated from a...
CEO Josh Riggs will be meeting with registered investors on September 11-12, 2023 IRVINE, CA, September 6, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, at the Lotte New York Palace Hotel. Josh Riggs, CEO of Oncocyte, will be meeting 1x1 with registered investors during the conference. The Company’s virtual presentation...
First digital-droplet PCR assay to receive coverage Expect initial revenue generation in Q1 2024 IRVINE, CA, August 28, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a positive coverage decision for the Company’s VitaGraft Kidney™ diagnostic test, confirming that the test has met the criteria for coverage under MolDX:...
Conference Call on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, August 10, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the second quarter of 2023, ended June 30, 2023. Second Quarter and Recent Highlights Transplant product launch on pace for Q4 early access. Manufacturing transfer process for 48-target universal assay began in June Expanding clinical utility for VitaGraft Kidney, a recent...
IRVINE, CA, August 9, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed. The Company was previously notified by Nasdaq on August 9, 2022 that it was not in compliance with the minimum bid price...
CEO Josh Riggs will be meeting with registered investors on Tuesday, August 15, 2023 IRVINE, CA, August 8, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference taking place on August 14-15th, 2023. Josh Riggs, CEO of Oncocyte, will be meeting 1x1 or in small groups with registered investors on Tuesday, August 15, 2023. Interested investors can register for...
Conference Call and Webcast on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, August 3, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, prior to the U.S. market open. The company will host a conference call and webcast on Thursday, August 10, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial results and...
